GPT and neoplasm: The ongoing Childrenʼs Oncology Group ANBL1531 phase 3 trial and planned European trial also integrating lorlatinib into frontline therapy will provide more definitive data on any relationship between age and anti-tumor activity and will interrogate ALT status for all enrolled patients.